Human neutralizing antibodies against hemolytic uremic syndrome

Details Human neutralizing antibodies against hemolytic uremic syndrome Human neutralizing antibodies against hemolytic uremic syndrome

2011-03-22

2011-03-22

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S141100, C424S142100, C424S150100, C424S169100

Reexamination Certificate

active

07910096

ABSTRACT:
Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg of patient weight. The examples demonstrate the preferred dosage ranges based on the pig model, and what is being tested in phase I clinical trials. Antibodies are preferably transfused over a period of two hours, although this will depend on the patient and the disease state at the time of treatment. Preferred dosages for treatment of humans are between 0.1 mg/kg-5.0 mg/kg of 5C120, or an equivalent dosage of another antibody to subunit A of STX2. In the most preferred embodiments, dosages of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of 5C12 (low dose, anticipated therapeutic dose based on animal data and high dose) are administered.

REFERENCES:
patent: 4689299 (1987-08-01), Insel et al.
patent: 5512282 (1996-04-01), Krivan et al.
patent: 5955293 (1999-09-01), Keusch et al.
patent: 6080400 (2000-06-01), Williams et al.
patent: 6255458 (2001-07-01), Lonberg et al.
patent: 2008/0038262 (2008-02-01), Tzipori et al.
patent: 2008/0107651 (2008-05-01), Tzipori et al.
patent: WO 90/07861 (1990-07-01), None
patent: WO 93/18784 (1993-09-01), None
patent: WO 97/13852 (1997-04-01), None
patent: WO 98/20903 (1998-05-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 99/59629 (1999-11-01), None
37 C.F.R. 1.132 declaration by Dr. Florian Gunzer, dated Apr. 1, 2003.
37 C.F.R. 1.132 declaration by Dr. John. M. Leong, dated Mar. 27, 2003.
37 C.F.R. 1.132 declaration by Dr. Saul Tzipori, dated Apr. 10, 2003.
Akiyoshi, et al., “Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in chinese hamster ovary cells”,Infect.Immun., 73:4054-61 (2005).
Baert, et al., “Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease”,N. Engl. J. Med., 348(7):601-8 (2003).
Banatvala, et al., “The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings”,J. Infect. Dis., 183(7):1063-70 (2001).
Besser, “Escherichia coliO157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease”,Annu.Rev.Med., 50:355-67 (1999).
Bielaszewska, et al. “Isolation and characterization of sorbitol-fermenting Shiga toxin (verocytotoxin)-producingEscherichia coli0157:H-strains in the Czech Republic”,J. Clin. Microbio., 36(7):2135-37 (1998).
Bielaszewska, et al., “Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits”,Infect. Immun., 65(7):2509-16 (1997).
Boerlin, et al., “Associations between virulence factors of Shiga toxin-producingEscherichia coliand disease in humans”,J. Clin. Microbiol., 37:497-503 (1999).
Bonnet, et al., “Non-O157:H7 Stx2-producingEscherichia colistrains associated with sporadic cases of hemolytic-uremic syndrome in adults”,J. Clin. Microbiol., 36(6):1777-80 (1998).
Bosworth, et al., “Vaccination with genetically modified Shiga-like toxin II prevents edema disease in swine”,Infect. Immun., 64:55-60 (1996).
Boyce, et al., “Escherichia coliO157:H7 and the hemolytic-uremic syndrome”,N. Engl. J. Med., 333(6):364-8 (1995).
Boyd, et al., “Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs”,J. Exp. Med., 177:1745-53 (1993).
Brooks, et al., “Non-O157 Shiga toxin-producingEscherichia coliinfections in the united states, 1983-2002”,J. Infect. Dis., 192:1422-1429 (2005).
CDC Drug Service “Diphtheria Antitoxin (Equine)”, inImmunobioloqics Distributed by the Centers of Disease Control and Prevention(2003).
Chalmers, et al., “The surveillance of vero cytotoxin-producingEscherichia coliO157 in Wales, 1990 to 1998”,Emerg. Infect. Dis., 5(4):566-9 (1999).
Cimolai, “A continuing assessment of risk factors for the development ofEscherichia coliO157:H7-associated hemolytic uremic syndrome”,Clin. Nephrol., 42(2):85-9 (1994).
Cornick, et al., “Escherichia coliO157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome”,J. Infect. Dis., 186(1):57-63 (2002).
Dean-Nystrom, et al., “Escherichia coliO157:H7 causes more-severe systemic disease in suckling piglets than in colostrum-deprived neonatal piglets”,Infect. Immun., 68:2356-2358 (2000).
Donohue-Rolfe, et al., “Antibody-based protection of gnotobiotic piglets infected withEscherichia coliO157:H7 against systemic complications associated with Shiga toxin 2”,Infect. Immun., 67:3645-3648 (1999).
Donohue-Rolfe, et al., “Escherichia coliO157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2”,J. Infect..Dis., 181:1825-9 (2000).
Donohue-Rolfe, et al., “Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies”,J. Exp. Med., 160(6):1767-81 (1984).
Donohue-Rolfe, et al., “Purification.Of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized p1 glycoprotein and production of cross-reactive monoclonal antibodies”,Infect. Immun. 57:3888-3893 (1989).
Donohue-Rolfe, et al., “Shiga toxin: purification, structure, and function”,Rev. Infect. Dis., 13 Suppl 4:S293-7 (1991).
Downes, et al., “Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies”,Infect. Immun., 56:1926-33 (1988).
Edwards, et al., “Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies againstEscherichia colitoxins Stx1 and Stx2”, inEscherichia coli 157:H7 and other Shiga toxin-producing E. coli strains(Kaper, et al. eds) American Society for Microbiology: Washington D.C., pp. 388-392 (1995).
Engleman, (by Kozbor and Croce), “Fusion partners for human mAbs”, inHuman Hybridomas and Monoclonal Antibodies, (Engleman, et al., eds.), Plenum Press: New York, pp. 23-27 (1985).
Engleman (by Bogard), et al., “Production and characterization of human monoclonal antibodies against gram-negative bacteria”, inHuman Hybridomas and Monoclonal Antibodies, (Engleman, et al., eds.), Plenum Press: New York, pp. 95-112 (1985).
Eklund, et al., “ClinicalEscherichia colistrains carrying Stx genes: Stx variants and Stx-positive virulence profiles”,J. Clin. Microbiol., 40(12):4585-93 (2002).
Francis, “Infection of gnotobiotic pigs with anEscherichia coliO157:H7 strain associated with an outbreak of hemorrhagic colitis”,Infect. Immun., 51:953-6 (1986).
Friedrich, et al., “Escherichia coliharboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms”,J Infect. Dis., 185:74-84 (2002).
Fukushima, et al., “Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagicEscherichia coliO157 infections in Sakai City, 1996”,Pediatr. Int., 41(2):213-7 (1999).
Gannon, “Characteristics of the Shiga-Like Toxin Produced ByEscherichia coliAssociated With Porcine Edema Disease”,Vet. Microbiol., 24:89-100 (1990).
Gannon, “Effects ofEscherichia coliShiga-like toxins (verotoxins) in pigs”,Can. J. Vet. Res., 53:306-12 (1989).
Garg, et al., “Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic

Affiliated with

Also associated with

Rating

Human neutralizing antibodies against hemolytic uremic syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human neutralizing antibodies against hemolytic uremic syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human neutralizing antibodies against hemolytic uremic syndrome will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2734522